Abstract
X-linked hypophosphataemia (XLH) rickets is a rare disease frequently misdiagnosed and mismanaged. Despite having clinical guidelines that offers some therapeutic recommendations based on the clinical experience of experts, physicians still have questions about some important aspects of the diagnosis and treatment of XLH, such as when the disease should be suspected, who should be in charge of the diagnosis, what should be done once the disease is diagnosed, or what therapeutic options are currently available. The objective of this paper is to answer some of the more frequent questions related to the management of patients with XLH by a group of experts participating in a scientific conference on XLH held in Madrid.
Similar content being viewed by others
Change history
23 May 2020
In the original article, third author name has been published incorrectly.
17 June 2020
In the original article, there is an error in age related reference.
References
Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL. A clinician’s guide to X-linked hypophosphatemia. J Bone Miner Res. 2011;26(7):1381–8.
Capelli S, Donghi V, Maruca K, et al. Clinical and molecular heterogeneity in a large series of patients with hypophosphatemic rickets. Bone. 2015;79:143–9.
Shopfner CE, Coin CG. Genu varus and valgus in children. Radiology. 1969;92(4):723–32.
Heath CH, Staheli LT. Normal limits of knee angle in white children - genu varum and genu valgum. J Pediatr Orthop. 1993;13(2):259–62.
Vega RA, Opalak C, Harshbarger RJ, et al. Hypophosphatemic rickets and craniosynostosis: a multicenter case series. J Neurosurg Pediatr. 2016;17(6):694–700.
del Pino M, Viterbo G, Fano V. Manejo de niños con raquitismo hipofosfatémico familiar 2017 [January 16]. http://www.garrahan.gov.ar/images/intranet/guias_atencion/GAP_2017_-_MANEJO_RAQUITISMO.pdf. Accessed 10 Feb 2019.
Bistarakis L, Voskaki I, Lambadaridis J, Sereti H, Sbyrakis S. Renal handling of phosphate in the first six months of life. Arch Dis Child. 1986;61(7):677–81.
Shaw NJ, Wheeldon J, Brocklebank JT. Indices of intact serum parathyroid hormone and renal excretion of calcium, phosphate, and magnesium. Arch Dis Child. 1990;65(11):1208–11.
Lambert AS, Linglart A. Hypocalcaemic and hypophosphatemic rickets. Best Pract Res Clin Endocrinol Metab. 2018;32(4):455–76.
Schaumberger E, Hohenauer L, Sommer R. Early diagnosis and early treatment of hypophosphatemic vitamin D-resistant rickets. Klin Padiatr. 1986;198(1):44–8.
Carpenter TO, Shaw NJ, Portale AA, Ward LM, Abrams SA, Pettifor JM. Rickets. Nat Rev Dis Primers. 2017;3:17101.
Elder CJ, Bishop NJ. Rickets. Lancet. 2014;383(9929):1665–76.
Goldsweig BK, Carpenter TO. Hypophosphatemic rickets: lessons from disrupted FGF23 control of phosphorus homeostasis. Curr Osteoporos Rep. 2015;13(2):88–97.
Payne RB. Renal tubular reabsorption of phosphate (TmP/GFR): indications and interpretation. Ann Clin Biochem. 1998;35(Pt 2):201–6.
Walton RJ, Bijvoet OL. Nomogram for derivation of renal threshold phosphate concentration. Lancet. 1975;2(7929):309–10.
Phelps K, Mason DL. Evidence that TmP/GFR can be estimated with the Walton-Bijvoet nomogram in chronic kidney disease. Clin Nephrol. 2017;88(1):19–26.
Lyseng-Williamson KA. Burosumab in X-linked hypophosphatemia: a profile of its use in the USA. Drugs Ther Perspect. 2018;34(11):497–506.
Imel EA, Econs MJ. Fibroblast growth factor 23: roles in health and disease. J Am Soc Nephrol. 2005;16(9):2565–75.
Liu S, Quarles LD. How fibroblast growth factor 23 works. J Am Soc Nephrol. 2007;18(6):1637–47.
Jonsson KB, Zahradnik R, Larsson T, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med. 2003;348(17):1656–63.
Riminucci M, Collins MT, Fedarko NS, et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest. 2003;112(5):683–92.
Igaki JM, Yamada M, Yamazaki Y, et al. High iFGF23 level despite hypophosphatemia is one of the clinical indicators to make diagnosis of XLH. Endocr J. 2011;58(8):647–55.
Imel EA, DiMeglio LA, Hui SL, Carpenter TO, Econs MJ. Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations. J Clin Endocrinol Metab. 2010;95(4):1846–50.
Ruppe MD, Zhang X, Imel EA, et al. Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia. Bone Rep. 2016;5:158–62.
Sullivan R, Abraham A, Simpson C, et al. Three-month randomized clinical trial of nasal calcitonin in adults with X-linked hypophosphatemia. Calcif Tissue Int. 2018;102(6):666–70.
Carpenter TO, Imel EA, Ruppe MD, et al. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J Clin Invest. 2014;124(4):1587–97.
Product information Phosphate Sandoz®. https://www.medicines.org.uk/emc/product/958/smpc. Accessed 10 Feb 2019.
Product information Fosfato NM®. http://cima.aemps.es/cima/pdfs/es/ft/81120/81120_ft.pdf. Accessed 10 Feb 2019.
Imel EA, White KE. Pharmacological management of X-linked hypophosphataemia. Br J Clin Pharmacol. 2019;85(6):1188–98.
Acknowledgements
This supplement has been funded by Kyowa Kirin.
Funding
Kyowa Kirin organized the scientific meeting and contributed to the financing of the publication of the opinion of the speakers presented at that meeting (Madrid, November 2018).
Authorship
All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.
Medical Writing, Editorial, and Other Assistance
The authors would like to thank Fernando Sánchez Barbero, PhD for providing medical writing assistance on behalf of Springer Healthcare. Kyowa Kirin funded the writing assistance. Ruth Blaikie provided the copy editing of this manuscript.
Disclosures
Josep-Vicent Torregrosa, Jaime Sánchez del Pozo and María Isabel Luis Yanes declare no conflict of interest for the publication of this manuscript. Manuel Muñoz Torres has participated as a speaker and in clinical studies sponsored by Kyowa Kirin.
Compliance with Ethics Guidelines
This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
Author information
Authors and Affiliations
Corresponding author
Additional information
Enhanced Digital Features
To view enhanced digital features for this article go to https://doi.org/10.6084/m9.figshare.11365145.
Rights and permissions
About this article
Cite this article
Torregrosa, JV., Sánchez del Pozo, J., Luiz Yanes, M.I. et al. Panel Discussion: Some Aspects of the Management of Patients with X-Linked Hypophosphataemic Rickets. Adv Ther 37 (Suppl 2), 121–126 (2020). https://doi.org/10.1007/s12325-019-01208-w
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-019-01208-w